



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>G01N 33/543, 33/566, 33/58</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/16833</b> <b>(43) International Publication Date:</b> 23 April 1998 (23.04.98)
<b>(21) International Application Number:</b> PCT/GB97/02552 <b>(22) International Filing Date:</b> 22 September 1997 (22.09.97)  <b>(30) Priority Data:</b> 9621256.8 11 October 1996 (11.10.96) GB  <b>(71) Applicant (for all designated States except US):</b> XENOVA LIMITED [GB/GB]; 240 Bath Road, Slough, Berkshire SL1 4EF (GB).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> MACALLAN, David [GB/GB]; Xenova Limited, 240 Bath Road, Slough, Berkshire SL1 4EF (GB).  <b>(74) Agents:</b> KEEN, Celia, Mary et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> DOUBLE LABEL IMMUNOASSAY  <b>(57) Abstract</b>  A solid phase assay comprising: (a) providing a solid support on which is immobilised a first component of a binding interaction between the first component and a second component, the first component having a first label which is non-radioactive; (b) contacting the said solid support either (i) with a putative inhibitor of the binding interaction and the second component of the binding interaction, the second component having a second label which is non-radioactive and which is distinguishable from the first label, under conditions under which the binding interaction, in the absence of inhibitor would be expected to occur, or (ii) with a specimen to be assayed for a predetermined analyte, which analyte is the second component of the binding interaction, under conditions under which the binding interaction would be expected to occur if the analyte is present in the specimen; and (c) determining whether, or to what extent, the binding interaction has occurred.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## DOUBLE LABEL IMMUNOASSAY

The present invention relates to an improved solid phase assay.

In conventional solid phase assays, a first component  
5 of a binding interaction between the first component and a second component is immobilised on a solid support. Any complex formed by the binding interaction is generally isolated on the solid support and the presence of the isolated complex is determined.

10 However, in such assays, errors can arise as some of the complex formed by the binding interaction may be lost. Loss of complex may occur if, for some reason, the first component immobilised on the solid support becomes dissociated therefrom. If some of the complex is lost  
15 before it can be detected, then subsequent determination of the amount of the complex will give an artificially low result, leading, in some cases, to false assay results.

The present invention seeks to provide a solid phase assay which incorporates an internal control to assess  
20 whether, or to what extent, the complex formed by the binding interaction is lost before it is determined.

Accordingly, the present invention provides a solid phase assay comprising:

(a) providing a solid support on which is  
25 immobilised a first component of a binding interaction between the first component and a second component, the

first component having a first label which is non-radioactive;

- (b) contacting the said solid support either (i) with a putative inhibitor of the binding interaction and the second component of the binding interaction, the second component having a second label which is non-radioactive and which is distinguishable from the first label, under conditions under which the binding interaction, in the absence of inhibitor would be expected to occur, or (ii) with a specimen to be assayed for a predetermined analyte, which analyte is the second component of the binding interaction, under conditions under which the binding interaction would be expected to occur if the analyte is present in the specimen; and
- (c) determining whether, or to what extent, the binding interaction has occurred.

The assay of the present invention is advantageous as the first label can function as an internal control to assess whether, or to what extent, the complex formed by the binding interaction is lost before it is determined. If complex is lost before it is determined, the signal generated by the first label will be inhibited.

The binding interaction can be, for example, (a) an interaction between a ligand and a receptor therefor, for example the binding of a cytokine, hormone, neurotransmitter, growth factor or peptide to a receptor therefor, (b) a protein/protein interaction such as the

binding of an antibody to an antigen or a signalling protein interaction, preferably an intracellular signalling protein interaction such as a ras-raf interaction or an interaction between cyclin and cyclin-dependent kinase or  
5 (c) an interaction between a DNA sequence and one or more protein which recognises the sequence.

The first component and/or the second component may consist of more than one substance. Thus, for example, the first component may consist of a DNA sequence and the  
10 second component may consist of two proteins which can together bind thereto. Either component of a given binding interaction may be the component immobilised on the solid support.

Preferably, the solid support is an optical quality  
15 surface, i.e. a surface that has minimal effect on a signal generation process and on a generated signal. The solid support typically comprises polystyrene beads or the wall of a reaction vessel. The solid support may therefore comprise the walls of a 96 well microtitration plate or the  
20 walls of a higher density plate. A higher density plate is a plate of the same footprint size as a 96 well microtitration plate having more than 96 wells. Typically, a higher density plate has about 384 wells.

Other suitable solid supports include optical fibres  
25 and glass or quartz surfaces such as quartz cuvettes, flat sheets of quartz or glass and quartz or glass rods.

Typically, the assay of the invention includes the

step of immobilising the first component of the binding interaction on the solid support. The first component can be immobilised on the solid support in any convenient manner such as by a protein capture technique. Typically, 5 the first component is covalently or non-covalently bound to a first substance and a second substance, capable of binding to the first substance, is adsorbed onto the solid support. Capture of the first substance by the second substance can then be effected.

10 Typically the first and second substances are, respectively, biotin and streptavidin, an antigen and an antibody therefor, a glutathione-S-transferase fusion protein and glutathione, or a histidine tagged protein and nickel.

15 Alternatively, the first component can be passively adsorbed onto the solid support.

In the assay of the present invention, the first and second labels are different. The signals generated by the first and second labels can be distinguished. Thus, the 20 components labelled with the first and second labels can be distinguished.

The first label and/or the second label is preferably fluorometrically detectable. More preferably the first label and/or the second label is fluorescein, calcein, 25 rhodamine or a mutant of green fluorescent protein. Preferred labels are those which are susceptible of quantitative determination. It is particularly preferred

that at least one, more preferably both, of the first and second labels are lanthanide ion labels such as samarium and europium ion labels.

Typically, a lanthanide ion label is a substantially  
5 non-fluorescent lanthanide ion complex covalently bound to the component in question, which is detectable by adding a developer comprising (a) a detergent and (b) a chelating compound with which the lanthanide ion gives fluorescence, thereby dissociating the lanthanide ion from the component  
10 and forming a fluorescent lanthanide ion chelate. Further details regarding the developer are given below.

The assay of the invention is typically either an assay for an inhibitor of a binding interaction or an assay of a specimen for a predetermined analyte.

15 An assay of the invention for an inhibitor of a binding interaction will now be described in more detail. Such an assay is shown in Figure 1.

Typically, an assay for an inhibitor of a binding interaction comprises:

20 (I) providing a solid support on which is immobilised a first component of a binding interaction between the first component and a second component, the first component having a first label which is non-radioactive;

25 (II) contacting the said solid support with the second component of the binding interaction and a putative inhibitor of the binding interaction under conditions under

which the binding interaction, in the absence of inhibitor, would be expected to occur, the second component having a second label which is non-radioactive and which is distinguishable from the first label; and

- 5 (III) determining whether the putative inhibitor inhibits the binding interaction.

A true positive result, where the putative inhibitor inhibits the interaction between the first and second components, will result in inhibition of the signal  
10 generated by the second label. However, the signal generated by the first label will not be inhibited.

A false positive result is generated when the amount of the complex formed by the binding interaction is reduced for any reason other than inhibition of the binding  
15 interaction by the putative inhibitor, for example if the putative inhibitor causes the first component to become dissociated from the solid support. In this event, the amount of complex isolated on the solid support in step (III) will be reduced and both the signal generated by the  
20 first label and the signal generated by the second label will be inhibited.

False positive results can therefore be detected by means of the present invention.

The conditions in step (II) above will obviously vary  
25 depending on the binding interaction but typically comprise incubation at from 10°C to 40°C, preferably at about room temperature, for from 30 minutes to 2 hours, preferably for



about 1 hour.

Step (III) is generally carried out by determining whether, or to what extent, the binding interaction has occurred. This can be done by determining the first and  
5 second components of the binding interaction. Typically, step (III) comprises (a) rinsing away unbound substances to isolate on the solid support any complex formed by the binding interaction and (b) determining the presence of the labels in the isolated complex.

10 If a substantially non-fluorescent lanthanide ion complex, as described above, is used as the first or second label, step (III b) above typically comprises the detection of the label by:

- 15 (A) adding to the solid support having the complex isolated thereon, a developer solution comprising (a) a detergent and (b) a chelating compound with which the lanthanide ion gives fluorescence.
- (B) allowing the lanthanide ion to dissociate from  
20 the component in question and to form a fluorescent chelate; and
- (C) determining the fluorescent chelate thereby obtained.

Preferably the lanthanide ion is a samarium or  
25 europium ion. Typically, the developer solution further comprises a buffer.

Preferably, the detergent is a non-ionic surfactant.

More preferably it is a polyoxyethylene ether such as an iso-octylphenoxypolyethoxyethanol in which the polyethoxy chain contains about ten ethoxy units (i.e. Triton X-100®). Preferably, the chelating compound is 2-

- 5 naphthoyltrifluoroacetone, tri-n-octylphosphine oxide or N<sup>1</sup>-(p-isothiocyanatobenzyl)-diethylenetriamine-N<sup>1</sup>, N<sup>2</sup>, N<sup>3</sup>, N<sup>4</sup>-tetraacetic acid. Preferably, the buffer is capable of maintaining a pH of from 3 to 4, more preferably about 3.2. Preferably, the buffer is an acetate-phthalate buffer.

- 10 Suitable developers are known in the art. An example of a suitable developer is DELFIA® Enhancement solution available from Wallac Oy.

Typically, step (B) is conducted by shaking the solid support with the said complex isolated thereon, in the  
15 presence of the developer solution, for from 5 to 20 minutes, for example about 10 minutes.

Greater sensitivity may be obtained by exciting the fluorescent chelates obtained in step (B) by means of a light impulse before determining the fluorescent chelate.  
20 During the interval between excitation and detection of the fluorescent chelates, the fluorescence from possible sources of interference decays.

Typically, fluorescent europium chelates are excited from 300 to 500  $\mu$ s, preferably about 400 $\mu$ s, before they are  
25 detected. Typically, fluorescent samarium chelates are excited from 40 to 60  $\mu$ s, preferably about 50  $\mu$ s, before they are detected. Typically, fluorescent terbium chelates

are excited from 80 to 120  $\mu$ s, preferably about 100 $\mu$ s, before they are detected. Typically, fluorescent dysprosium chelates are detected from 20 to 40  $\mu$ s, preferably about 30  $\mu$ s, before they are detected.

5 Typically, the light impulse is produced by a xenon flash lamp with a flash duration of about 1  $\mu$ s. The wavelength of the light impulse is typically from 320-340 nm.

Typically the light impulse is generated, and the  
10 fluorescence is subsequently detected, in a fluorometer such as the Wallac 1234<sup>®</sup> fluorometer or the Wallac 1420 Victor Multilabel Counter<sup>®</sup>.

In an assay of the present invention, which is an assay for an inhibitor of a binding interaction, the effect  
15 of a putative inhibitor on two or more different bioaffinity reactions can be investigated in the same assay. Thus, the effect of a putative inhibitor on one or more binding interactions can be investigated simultaneously. In such a multiplex assay, in step (a) of  
20 the assay of the invention a labelled first component of each binding interaction is provided on the solid support and in step (b) of the assay of the invention a labelled second component of each binding interaction is contacted with the solid support and the putative inhibitor, the  
25 labels for each first component typically being distinguishable from each other and the labels for each second component typically being distinguishable from each

other.

The second component of each binding interaction has a label which can be distinguished from the label of the first component of each binding interaction.

5       The same label can be used for each second component, in which case any specific inhibition of any of the binding interactions would result in a decrease in the signal generated by the label attached to each second component without a corresponding decrease in any of the signals  
10 generated by the labels attached to the first components.

      The same label can be used for each first component, in which case any non-specific inhibition of any of the binding interactions would result in a decrease in the signal generated by the label attached to each first  
15 component.

      If the labels of each of the first components and each of the second components can all be distinguished from one another, it will be possible to assess the effect of the putative inhibitor on each binding interaction.

20       A particularly preferred assay for an inhibitor of a binding interaction is an assay wherein the first component is tumour necrosis factor  $\alpha$  (TNF $\alpha$ ) and the second component is the p55 or p75 receptor protein. Preferably, both TNF $\alpha$  and the p55 or p75 receptor protein are labelled with a  
25 substantially non-fluorescent lanthanide ion complex as described above. Such a complex can be detected by steps (A) to (C), as described above. Preferably, the TNF $\alpha$  is

labelled with a samarium complex and the p55 or p75 protein is labelled with a europium complex.


TNF $\alpha$  is typically immobilised on a solid phase by biotinylation followed by capture with streptavidin which  
5 is adsorbed to the solid phase. Preferably, the biotinylated TNF $\alpha$  is immobilised onto plates which are precoated with streptavidin.


It is found that, when TNF $\alpha$  is the first component in the preferred assay described above, non-specific binding  
10 is significantly lower than in previous TNF $\alpha$ /receptor protein screening assays. In previous TNF $\alpha$ /receptor protein screen assays, the receptor protein has been immobilised on the solid phase. Non-specific binding consists of all binding between the second component and  
15 the solid phase other than binding between the second component and the first component. Non-specific binding can lead to false assay results and a reduction in non specific binding is advantageous.


The use of lanthanide labels in the preferred  
20 TNF $\alpha$ /receptor protein assay is also advantageous. In previous TNF $\alpha$ /receptor protein assays, [<sup>125</sup>I] labelled TNF $\alpha$  has been detected. It is not possible to determine the [<sup>125</sup>I] labelled TNF $\alpha$  as accurately as the lanthanide labelled component.

25 Figure 1 shows an assay for the detection of inhibitors of the TNF $\alpha$  and p55 receptor binding interaction. In the assay shown in Figure 1, the first

component of the binding interaction is tumour necrosis factor  $\alpha$  (TNF $\alpha$ ). The TNF $\alpha$  is covalently bound to biotin, which is adsorbed to streptavidin on the solid phase. The second component of the binding interaction is p55 receptor protein. The TNF $\alpha$  is labelled with a samarium ion label and the p55 receptor protein is labelled with a europium ion label. In Figure 1, the various symbols have the following meanings:

10  - Natural product inhibitor

 - Samarium - TNF $\alpha$  - biotin

 - p55-Europium

15  - Streptavidin

A - FluoroNunc 96 well plate or 384 well white Nanoplates

20

The present invention also provides a test kit suitable for an assay for an inhibitor of a binding interaction which test kit comprises:

- (a) a solid support; and
- 25 (b) labelled first and second components of a binding interaction, as defined above.

Preferably, in the above test kit of the invention,

the first component is immobilised on the solid support.

An assay of the invention which is an assay of a specimen for a predetermined analyte will now be described in more detail.

5       A solid phase assay, conducted to determine whether a specimen contains a predetermined analyte, typically comprises:

(I)    providing a solid support on which is immobilized a first component of a binding interaction  
10   between the first component and a second component, the first component having a first label which is non-radioactive;

(II)   contacting the said solid support with a specimen to be assayed for a predetermined analyte, which  
15   analyte is the second component of the binding interaction, under conditions under which the binding interaction would be expected to occur if the analyte is present in the specimen; and

(III)   determining whether the analyte is present in  
20   the specimen.

The analyte is typically a substance of diagnostic significance, such as an antibody to a pathogen or an antigen recognised by such an antibody. The first component is typically an antibody or a DNA sequence.

25       The conditions in step (II) generally comprise incubation at from 18°C to 40°C, preferably at about 37°C. The incubation period will depend on the particular binding

interaction but is typically from 10 to 60 minutes, for example about 30 minutes.

Preferably the specimen is a serum, plasma, urine, saliva, or cerebrospinal fluid specimen, more preferably a serum or plasma specimen.

Step (III) is generally carried out by determining whether, or to what extent, the binding interaction has occurred. This can be done by determining the first component of the binding interaction and the complex formed by the binding interaction.

In step (III), the complex formed by the binding interaction is typically determined by (a) rinsing away unbound specimen components to isolate on the solid support any complex formed by the binding interaction, (b) adding a further reactant which recognises the said complex and which is labelled and (c) determining the label of the further reactant.

The label of the further reactant is distinguishable from the first label. It can be detected by conventional methods. It may be any conventional label such as an enzyme label, a fluorescent label or a radioactive label.

When the analyte is a human antibody, the further reactant can be anti-human IgG conjugated with the enzyme horseradish peroxidase (hrp). The hrp conjugated anti-human IgG binds to complex formed by the binding interaction. Unbound anti-human IgG may be rinsed away and the bound anti-human IgG may be detected by adding a



chromogenic substance containing tetramethyl benzidine (TMB). This reacts with the hrp conjugated to the anti-human IgG to form a blue coloured product. The optical density of the resulting solution is directly proportional to the amount of the complex formed by the binding interaction.

The first label is preferably a substantially non-fluorescent lanthanide ion complex, as described above. It can be detected by steps (A) to (C), as described above.

10 If the first component should be become dissociated from the solid support, the signal generated by the first label will be inhibited. Thus, one source of false negative results can be detected by means of the present invention.

15 The present invention also provides a test kit suitable for an assay of a specimen for a predetermined analyte, which test kit comprises a solid support upon which is immobilised a labelled first component of a binding interaction as defined above.

20 In its broadest aspect, the present invention provides a solid phase assay in which (i) a solid support is provided, upon which a first component of a binding interaction between the first component and a second component is immobilised, (ii) a step is carried out in which the second component may bind to the first component and (iii) whether, or to what extent, the binding interaction has occurred is determined,

25

wherein the first component is labelled with a non-radioactive label.

Reference Example 1

5           Lyophilised protein carrier free TNF $\alpha$  was reconstituted in sodium carbonate buffer at pH 9.6. It was then simultaneously labelled with biotin and samarium (Sm) chelate by incubation with biotin- $\epsilon$ -aminocaproic acid-N-hydroxysuccinimide ester and samarium chelated with N<sup>1</sup>-(p-  
10 isothiocyanatobenzyl)-diethylenetriamine-N<sup>1</sup>, N<sup>2</sup>, N<sup>3</sup>, N<sup>4</sup>-tetraacetic acid for 18 hours at 4°C. The labelled protein was purified by gel filtration chromatography, with an 80% yield. The concentration of the purified labelled protein was estimated to be 80 $\mu$ g/ml. The labelling ratio was  
15 calculated to be 0.5:0.7:1 Sm:biotin:TNF $\alpha$ . The labelled purified protein was stabilised with 1 mg/ml Bovine Serum Albumin (BSA) and stored at -70°C.

A Tris-HCl buffered NaCl assay buffer solution (pH 7.8) containing 0.05% NaN<sub>3</sub>, BSA, Bovine gamma globulins,  
20 Tween 40, diethylenetriaminepentaacetic acid and an inert red dye (available from Wallac Oy as DELFIA® assay buffer) was used for diluting the labelled protein. Streptavidin coated 96 well polystyrene plates of good optical quality were used to capture the Sm-TNF $\alpha$ -biotin. Increasing  
25 concentrations of Sm-TNF $\alpha$ -biotin were added to streptavidin coated wells (100  $\mu$ l/well) and incubated for 1 hour at room temperature with shaking.

The plates were then washed six times with 250  $\mu$ l of a Tris-HCl buffered salt solution wash buffer (pH 7.8) containing Tween 20 and Germall as a preservative (available from Wallac Oy as DELFIA<sup>®</sup> wash buffer).

5        100  $\mu$ l of an enhancement solution containing an iso-octylphenoxypolyethoxyethanol in which the polyethoxy chain contains about ten ethoxy units (Triton X-100<sup>®</sup>), 2-naphthoyltrifluoroacetone, and tri-n-octylphosphine oxide in acetate-phthalate buffer at pH 3.2 (available from  
10 Wallac Oy as DELFIA<sup>®</sup> enhancement solution) was then added. After shaking for 10 minutes to allow dissociation enhancement of the lanthanides, the samarium signals were measured in the Wallac 1234<sup>®</sup> fluorometer. The results are shown in Table 1.

Table 1Titration of Sm-TNF $\alpha$ -Biotin Coating Concentration

Sm-TNF $\alpha$ -Biotin Signal			
	ng/well	Average	Standard Error of Mean
5	0	239	9
	0.5	384	16
	1	581	18
	2	922	11
	5	2588	98
10	10	6749	72
	20	16884	165
	30	25196	1234
	40	36380	652
	50	44532	323
15	60	56427	775
	70	62657	612

Binding was observed to increase linearly with increasing concentrations of Sm-TNF $\alpha$ -biotin.

20

Reference Example 2

Lyophilised protein carrier free recombinant p55 receptor protein was reconstituted in sodium carbonate buffer at pH 9.6. It was then labelled with europium (Eu) chelate by incubation with europium chelated with N<sup>1</sup>-(p-isothiocyanatobenzyl)-diethylenetriamine N<sup>1</sup>, N<sup>2</sup>, N<sup>3</sup>, N<sup>4</sup>-tetraacetic acid for 18 hours at 4°C. The labelled protein

was purified by gel filtration chromatography, with an 80% yield. The concentration of the purified labelled protein was estimated to be 80 $\mu$ g/ml. The labelling ratio was calculated to be 2.1:1 Eu:p55. The labelled purified  
5 protein was stabilised with 1mg/ml BSA and stored at -70°C.

An assay buffer as described in Reference Example 1 was used for diluting the labelled protein. Streptavidin-coated 96 well plates to which Sm-TNF $\alpha$ -biotin was bound  
10 were prepared as in Reference Example 1 using 20ng Sm-TNF $\alpha$ -biotin per well. These plates were then washed three times with 250  $\mu$ l of a wash buffer as described in Reference Example 1. The purified p55-Eu was then added at various concentrations (100 $\mu$ l/well) and incubated at room  
15 temperature with shaking for 2 hours.

The plates were then washed six times with 250  $\mu$ l of the above wash buffer and 100 $\mu$ l of the enhancement solution described in Reference Example 1 was added. After shaking for 10 minutes to allow dissociation enhancement of the  
20 lanthanides, the samarium and europium signals were measured in a Wallac 1234<sup>®</sup> fluorometer. Non-specific binding was measured by repeating the experiment using streptavidin-coated plates to which no Sm-TNF $\alpha$ -biotin was bound. The results are shown in Table 2.

Table 2

Saturation of p55-Eu Binding to Sm-TNF $\alpha$ -Biotin

Total Binding - Eu Signal			Non-specific Binding - Eu signal		
[p55-Eu] (M)	Average	Standard Error of Mean	[p55-Eu] (M)	Average	Standard Error of Mean
0	930	42	0	261	16
1.00E-11	3861	102	1.00E-11	253	14
3.00E-11	10325	205	3.00E-11	237	7
1.00E-10	29693	799	1.00E-10	274	22
3.00E-10	87774	3415	3.00E-10	241	5
1.00E-09	231898	5889	1.00E-09	308	34
3.00E-09	519891	8226	3.00E-09	313	25
1.00E-08	786687	44825	1.00E-08	378	73
3.00E-08	1086753	37327	3.00E-08	362	24
1.00E-07	1249340	16469	1.00E-07	604	79
3.00E-07	1349215	84382	3.00E-07	921	40

Sm-TNF $\alpha$ -Biotin signal		
[p55-Eu] (M)	Average	Standard Error of Mean
0	16357	201
1.00E-11	14834	462
3.00E-11	15812	469
1.00E-10	15328	473
3.00E-10	15889	629
1.00E-09	16259	376
3.00E-09	16738	382
1.00E-08	16274	712
3.00E-08	16459	762
1.00E-07	16442	642
3.00E-07	17037	574

Total binding for p55-Eu was found to saturate with a maximum signal of from 1,200,000 to 1,400,000 europium counts. The non-specific binding was very low at 300 - 2,000 europium counts over this range of p55-Eu

5 concentrations. Therefore this assay had a 700-4,000 fold window (assay window = total binding/non-specific binding).

Half maximal binding at 600,000-800,000 europium counts was achieved at a p55-Eu concentration of from 5 to 10 nM. This would be equivalent to the Kd value for the  
10 binding of TNF $\alpha$  to p55 protein. However, the exact concentration of p55 at which half maximal binding was achieved could not be accurately determined. Therefore, a displacement experiment using unlabelled p55 to compete with the p55-Eu (see below) was performed to calculate Kd.

15 The level of Sm-TNF $\alpha$ -biotin bound in this experiment gave the expected signal of from 15,000 to 17,000 samarium counts and was uniform across the plate.

#### Example 1

20

Inhibition of p55-Eu binding to Sm-TNF $\alpha$ -biotin by unlabelled p55 over the range  $10^{-11}$  -  $10^{-6}$  M was determined. A fixed final concentration of 7nM p55-Eu was used as this represents the approximate Kd value obtained in Reference  
25 Example 2. The assay was conducted in the same way as in Reference Example 2 except that, as explained above, a fixed concentration of p55-Eu was used and unlabelled p55

was added, together with the europium labelled p55, at various concentrations (100 $\mu$ l/well final volume). The results are shown in Table 3.

Table 3

Inhibition of p55-Eu by Unlabelled p55

p55-Eu Signal			Sm-TNF $\alpha$ -Biotin Signal		
[p55] (M)	Average	Standard Error of Mean	[p55] (M)	Average	Standard Error of Mean
1.00E-11	701602	15820	1.00E-11	14844	343
3.00E-11	715996	14948	3.00E-11	15145	337
1.00E-10	691250	23129	1.00E-10	15101	513
3.00E-10	640688	30800	3.00E-10	15298	737
1.00E-09	520921	6481	1.00E-09	15623	238
3.00E-09	244664	12082	3.00E-09	15064	446
1.00E-08	78544	4101	1.00E-08	15341	552
3.00E-08	24181	1113	3.00E-08	14949	485
1.00E-07	8451	337	1.00E-07	15537	542
3.00E-07	3870	885	3.00E-07	14615	441
1.00E-06	1578	57	1.00E-06	14333	304

The results in Table 3 show 50% inhibition at 1.9nM. This gives a close approximation to the K<sub>d</sub> for p55-Eu binding. However, a more accurate indication of the K<sub>d</sub> can be obtained by calculating the K<sub>i</sub> from the IC<sub>50</sub> (the concentration at which 50% of the binding is inhibited)

using the Cheng-Prusoff equation:

$$K_i = IC_{50} / (1 + L / K_d) \text{ where } L = \text{p55-Eu concentration.}$$

In this case L should equal the K<sub>d</sub>. Thus:

$$K_i = IC_{50} / 2$$



Therefore, the  $K_i$  for p55 inhibition of p55-Eu is found to be 0.95 nM which is equivalent to literature values for the  $K_d$  of the p55 receptor (0.3 - 1.0 nM). The control samarium signal was as expected in the assay at  
5 around 15,000 samarium counts.

### Reference Example 3

In Example 1 and Reference Example 2, a 2 hour  
10 incubation period was used for binding of the p55-Eu to the Sm-TNF $\alpha$ -biotin. To determine an optimum incubation time, a time course of binding of p55-Eu to Sm-TNF $\alpha$ -biotin at a fixed final concentration of 7nM was performed with 15 minute time points. The assay was conducted in the same  
15 way as in Reference Example 2 except that, as explained above, the concentration of p55-Eu was fixed at 7nM and the incubation time was varied. The results are shown in Table 4.

**Table 4**Time Course for p55 Binding

p55-Eu Signal						
Time	Total Binding		Non-specific Binding		Sm-TNF $\alpha$ -Biotin Signal	
(min)	Average	Standard Error of Mean	Average	Standard Error of Mean	Average	Standard Error of Mean
15	634846	29296	312	16	16227	455
30	747059	18120	324	22	17314	478
45	773710	12773	340	43	17681	211
60	791242	14181	316	30	17597	456
75	805514	15279	361	25	17585	439
90	809398	26920	367	27	17618	564
105	798321	29524	382	40	16755	687
120	799861	20818	366	34	16543	536

The results in Table 4 demonstrate that p55-Eu binding to Sm-TNF $\alpha$ -biotin is rapid and has reached equilibrium by 60 minutes.

Reference Example 4

A Sm-TNF $\alpha$ -biotin complex was prepared as described in Reference Example 1. The labelled protein was diluted with the Tris-HCl buffered NaCl assay buffer described in Reference Example 1. 384 well white polystyrene plates of good optical quality were coated with 40  $\mu$ g/ml streptavidin overnight at 4°C. These streptavidin coated plates were used to capture the Sm-TNF $\alpha$ -biotin. The plates were first

blocked using 2% BSA and then increasing concentrations of Sm-TNF $\alpha$ -biotin were added to the streptavidin coated wells (total volume 50  $\mu$ l/well). Incubation then took place for 1 hour with shaking.

- 5 The samarium ions were determined as described in Reference Example 1. The results are shown in Table 5.

Table 5

Titration of Sm-TNF $\alpha$ -Biotin Coating Concentration

10	Sm-TNF $\alpha$ -Biotin Signal		
	ng/wells	Average Sm-TNF $\alpha$ -Biotin signal	Standard error of mean
	0	342	16
	1.875	4359	153
	3.75	7931	532
15	7.5	13988	402
	15	21638.75	838
	30	27964	2083
	60	36012.75	205
	120	47356	261
20	240	53276.5	894
	480	57301.25	3311

Reference Example 5

- 25 Purified p.55 receptor protein labelled with europium chelate was prepared as described in Reference Example 2. Streptavidin coated 384 well plates to which Sm-TNF $\alpha$ -biotin was bound were prepared as in Reference Example 5 using 50

$\mu$ l of 120 ng/ml Sm-TNF $\alpha$ -biotin. The plates were then washed three times with a wash buffer as described in Reference Example 1. The purified p.55-Eu was then added at various concentrations (total volume 50 $\mu$ l/well).

- 5 Incubation took place at room temperature with shaking for 2 hours.

The europium ions were determined as in Reference Example 2. The results are shown in Table 6.

Table 6

10 Saturation of p55-Eu binding to the Sm-TNF $\alpha$ -Biotin

[p55-Eu] $\mu$ M	Average Eu signal	Standard of error of mean
0	3035	209
0.0003	157064	19461
0.0007	361555	19371
15 0.0014	671915	13578
0.0027	1049680	35934
0.0054	1492000	79303
0.0109	2021490	131363
0.0210	2154510	99581
20 0.0437	2441790	111060
0.0874	2638210	117080
0.1749	2946350	149617
0.3498	3075610	205654

- 25 Total binding for p55-Eu was found to saturate with a maximum signal of approximately 3,000,000 europium counts, with non-specific binding at 3000 europium counts. This gave an assay window of 1000 fold (assay window = total

binding/non-specific binding). Half-maximal binding at 1,500,000 europium counts was achieved at a p55-Eu concentration of approximately 5.3nM. This would be equivalent to the Kd value for the binding of TNF $\alpha$  to p55.

5 However, the exact concentration of p55 at which half-maximal binding was achieved could not be accurately determined. Therefore, a displacement experiment using unlabelled p55 was performed to calculate the Kd, as in Example 1.

10

#### Example 2

Inhibition of p55-Eu binding to Sm-TNF $\alpha$ -biotin by unlabelled p55 was determined. The assay was conducted in  
15 the same way as in Reference Example 5 except that a fixed concentration of 120 ng/ml Sm-TNF $\alpha$ -biotin was used and unlabelled p55 was used, together with the europium labelled p55, at various concentrations. The results are shown in Table 7.

20

Table 7Inhibition of p55-Eu binding by unlabelled p55

p55-Eu Signal		
[p55] ( $\mu$ M)	Average p55-Eu signal	Standard error of mean
3.55 E-7	3579560	7463
1.77 E-6	3586380	6944
8.8 E-6	3583760	6177
4.4 E-5	3552030	34637
2.2 E-4	3441980	10076
1.1 E-3	3236970	63011
5.5 E-3	1775460	60112
2.78 E-2	207993	18330
1.39 E-1	46732	1425
5.56 E-1	20260	716

The results in Table 7 show 50% inhibition at a p55 concentration of 4.12nM. The Cheng-Prusoff equation was used to determine the p55  $K_i$  and hence p55-Eu  $K_d$  from the p55  $IC_{50}$ , as shown in Example 1.

$K_i = IC_{50} / (1 + L / K_d)$  where  $L$  = ligand concentration which in this case was 2 x estimated  $K_d$  or 10.6nM.

Therefore, the  $K_i$  for the p55 inhibition of p55-Eu for the 384 well format was found to be 1.37nM which is close to the literature quoted values.

Reference Example 6

An optimum incubation time for binding of the p55-Eu to the Sm-TNF $\alpha$ -Biotin was determined by carrying out an assay in the same way as in Reference Example 5 except that the concentration of p55-Eu was fixed at 2nM and the incubation time was varied. The results are shown in Table 8.

Table 8Time course for p55 binding

p55-Eu Signal				
Time (mins)	Total Binding	Total Binding	Non-specific binding	Non-specific binding
	Average	Standard error of mean	Average	Standard error of mean
0	0	0	0	0
15	278389	42071	33296	436
30	400000	54733	63159	829
45	470000	28043	24084	1523
60	469828	30365	63845	551
75	466837	28661	73256	711
120	448198	43163	25063	2112
160	448830	29365	63669	873

Reference Example 7

The use of different assay plates was investigated for both the 96 and 384 well assay formats. In both cases clear, white and black plates were evaluated.

96 well plates were coated with streptavidin as in Reference Example 4, but using a total volume of 100 $\mu$ l in each reagent and wash step. Sm-TNF $\alpha$ -biotin at 120ng/ml (100 $\mu$ l) was then added and incubated for one hour at room temperature with shaking. The plates were then washed three times with a wash buffer as described in Reference Example 1 prior to the addition of 7.7nM p55-Eu (100 $\mu$ l total volume). After a further 1 hour incubation the plates were washed six times with the above wash buffer and 100 $\mu$ l of the enhancement solution described in Reference Example 1 was added. After shaking to allow dissociation enhancement of the lanthanides, the plates were mixed and the samarium and europium signals were determined using a Wallac Victor 1420 reader. Clear, black and white plates were handled identically.

Clear, black and white 384 well plates were handled in the same manner, but with total volumes in each reagent addition stage of 50 $\mu$ l.

Tables 9, 10 and 11 show the data for the 96 well plates. Tables 12, 13 and 14 show the data for the 384 well plates.



Table 9

Data obtained using clear 96 well plates  
in the TNF $\alpha$  dual labelled assay

		Average count	Standard deviation from the mean	Assay window
5	Average europium count for Totals	36905	5979	72
	Average europium count for NSBs	515	134	
10	Average samarium count for Totals	2834	122	21
	Average samarium count for NSBs	134	13	

Table 10

15 Data obtained using black 96 well plates  
in the TNF $\alpha$  dual labelled assay

		Average count	Standard deviation from the mean	Assay window
20	Average europium count for Totals	29946	7538	133
	Average europium count for NSBs	226	32	
25	Average samarium count for Totals	1584	277	90
	Average samarium count for NSBs	18	3	

Table 11

Data obtained using white 96 well plates  
in the TNF $\alpha$  dual labelled assay

		Average count	Standard deviation from the mean	Assay window
5	Average europium count for Totals	585471	36952	72
	Average europium count for NSBs	8099	234	
10	Average samarium count for Totals	38654	2506	97
	Average samarium count for NSBs	243	6	

The TOTAL values are those obtained adding both Sm-  
15 TNF $\alpha$ -biotin and p55-Eu in the assay. The NSB (non-specific  
binding) refer to those values obtained using p55-Eu alone.  
The concentrations used were 120ng/ml SM-TNF $\alpha$ -biotin and  
7.7nM p55-Eu.

Table 12

Data obtained using clear 384 well plates  
in the TNF $\alpha$  dual labelled assay

		Average count	Standard deviation from the mean	Assay window
5	Average europium count for Totals	52175	4966	109
	Average europium count for NSBs	477	55	
10	Average samarium count for Totals	3369	334	18
	Average samarium count for NSBs	188	38	

Table 13

15 Data obtained using black 384 well plates  
in the TNF $\alpha$  dual labelled assay

		Average count	Standard deviation from the mean	Assay window
20	Average europium count for Totals	37670	11970	241
	Average europium count for NSBs	156	33	
25	Average samarium count for Totals	2744	483	164
	Average samarium count for NSBs	17	8	

Table 14

Data obtained using white 384 well plates  
in the TNF $\alpha$  dual labelled assay

		Average count	Standard deviation from the mean	Assay window
5	Average europium count for Totals	294887	33255	228
	Average europium count for NSBs	1292	655	
10	Average samarium count for Totals	16586	1795	151
	Average samarium count for NSBs	110	19	

The TOTAL values are those obtained adding both Sm-  
 15 TNF $\alpha$ -biotin and p55-Eu in the assay. The NSB (non-specific  
 binding) refer to those values obtained using p55-Eu alone.  
 The concentrations used were 120ng/ml SM-TNF $\alpha$ -biotin and  
 7.7nM p55-Eu.

The data in Tables 9, 10, 11, 12, 13 and 14 show that  
 20 this assay system works well and provides significant  
 counts and assay windows (assay window = total counts/NSB  
 counts) in clear, white and black plates for both the 96  
 and 384 well formats.

CLAIMS

1. A solid phase assay comprising:

(a) providing a solid support on which is

5 immobilised a first component of a binding interaction between the first component and a second component, the first component having a first label which is non-radioactive;

(b) contacting the said solid support either (i)

10 with a putative inhibitor of the binding interaction and the second component of the binding interaction, the second component having a second label which is non-radioactive and which is distinguishable from the first label, under conditions under which the binding interaction, in the  
15 absence of inhibitor would be expected to occur, or (ii) with a specimen to be assayed for a predetermined analyte, which analyte is the second component of the binding interaction, under conditions under which the binding interaction would be expected to occur if the analyte is  
20 present in the specimen; and

(c) determining whether, or to what extent, the binding interaction has occurred.

2. An assay according to claim 1 wherein the first and second labels are fluorometrically detectable.

25 3. An assay according to claim 1 or 2 wherein the binding interaction is an interaction between a ligand and a receptor therefor.

4. An assay according to claim 1 or 2 wherein the binding interaction is a protein/protein interaction.

5. An assay according to claim 1 or 2  
5 wherein the binding interaction is an interaction between a DNA sequence and one or more protein which is capable of binding thereto.

6. An assay according to any one of the preceding claims wherein the first label and/or the second  
10 label is a substantially non-fluorescent lanthanide ion complex covalently bound to the component in question, which is detectable by adding a developer comprising (a) a detergent and (b) a chelating compound with which the lanthanide ion gives fluorescence, thereby dissociating the  
15 lanthanide ion from the component and forming a fluorescent lanthanide ion chelate.

7. An assay according to any one of the preceding claims in which the effect of a putative inhibitor on two or more binding interactions can be  
20 investigated simultaneously, wherein in step (a) a labelled first component of each binding interaction is provided on the solid support and in step (b) a labelled second component of each binding interaction is contacted with the solid support and the putative inhibitor, the labels for  
25 each first component being distinguishable from the labels for each second component.

8. An assay according to claim 7 wherein

each first component has the same label.

9. An assay according to claim 7 or 8 wherein each second component has the same label.

10. An assay according to any one of the  
5 preceding claims wherein the first component is tumour necrosis factor  $\alpha$  (TNF $\alpha$ ) and the second component is p55 or p75 receptor protein.

11. A test kit suitable for an assay according to any one of the preceding claims which test kit  
10 comprises:

- (a) a solid support; and
- (b) labelled first and second components as defined in claim 1.

12. A test kit according to claim 11 wherein  
15 the first component is immobilised on the solid support.

13. A process for identifying an inhibitor of a binding interaction, which process comprises:

(I) carrying out steps (a), (b)(i) and (c) as specified in claim 1; and, if the putative inhibitor does  
20 not inhibit the binding interaction;

(II) repeating (I) using a different putative inhibitor in step (b)(i).

14. An inhibitor of a binding interaction identified by the process of claim 13.

25 15. An assay according to claim 1 wherein the specimen to be assayed for a predetermined analyte is a serum, plasma, urine, saliva or cerebrospinal fluid

specimen.

16. An assay according to claim 1 or 15 wherein the analyte is an antibody to a pathogen or an antigen recognised by such an antibody.


5 17. A test kit suitable for an assay of a specimen for a predetermined analyte, which test kit comprises a solid support upon which is immobilised a labelled first component of a binding interaction as defined in any one of the preceding claims.

10 18. A solid phase assay in which (i) a solid support is provided, upon which a first component of a binding interaction between the first component and a second component is immobilised, (ii) a step is carried out in which the second component may bind to the first  
15 component and (iii) whether, or to what extent, the binding interaction has occurred is determined,

wherein the first component is labelled with a non-radioactive label.



FIGURE 1



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02552

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/543 G01N33/566 G01N33/58

According to International Patent Classification(IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 271 974 A (EKINS ROGER PHILIP) 22 June 1988 see claims 1-9,11,12 see page 11, line 7 - page 12, line 2; figure 1	1-18
X	PATENT ABSTRACTS OF JAPAN vol. 016, no. 276 (P-1374), 19 June 1992 & JP 04 072564 A (MITSUBISHI KASEI CORP), 6 March 1992, see abstract	1-18
A	EP 0 093 613 A (SYVA CO) 9 November 1983 Whole document	1-18
A	WO 91 00519 A (TRITON BIOSCIENCES INC) 10 January 1991 Whole document	1-18

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 December 1997

Date of mailing of the international search report

05/01/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Routledge, B

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02552

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0271974 A	22-06-88	AU 614935 B	19-09-91
		AU 7755987 A	24-02-88
		CA 1284620 A	04-06-91
		DE 3784465 A	08-04-93
		DK 183088 A	05-04-88
		EP 0318491 A	07-06-89
		FI 92881 C	10-01-95
		FI 92881 B	30-09-94
		WO 8801058 A	11-02-88
		JP 1503405 T	16-11-89
		KR 9610696 B	07-08-96
		US 5171695 A	15-12-92
EP 0093613 A	09-11-83	US 4533629 A	06-08-85
		US 4540659 A	10-09-85
		AU 560535 B	09-04-87
		AU 1411083 A	10-11-83
		BR 8302286 A	03-01-84
		CA 1193193 A	10-09-85
		DE 3377744 A	22-09-88
		HK 96090 A	23-11-90
		IN 156680 A	12-10-85
		JP 1857426 C	27-07-94
		JP 58206966 A	02-12-83
		JP 2651060 B	10-09-97
		JP 5209886 A	20-08-93
		US 5342759 A	30-08-94
		US 4843000 A	27-06-89
		US 4849338 A	18-07-89
		US 5432057 A	11-07-95
WO 9100519 A	10-01-91	DE 69008178 D	19-05-94
		DE 69008178 T	06-10-94
		EP 0479929 A	15-04-92
		US 5506109 A	09-04-96

**THIS PAGE BLANK (USPTO)**